Mon, April 12, 2021
Fri, April 9, 2021
Thu, April 8, 2021
Wed, April 7, 2021
Tue, April 6, 2021
Mon, April 5, 2021
Sun, April 4, 2021
Thu, April 1, 2021
Wed, March 31, 2021
Tue, March 30, 2021

Vamil Divan Downgraded (ACAD) to Hold and Held Target at $25 on, Apr 6th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -hold-and-held-target-at-25-on-apr-6th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Vamil Divan of Mizuho, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Held Target at $25 on, Apr 6th, 2021.

Vamil has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 4 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021
  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021


These are the ratings of the 3 analyists that currently disagree with Vamil


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $43 on, Tuesday, March 9th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021

Publication Contributing Sources